Literature DB >> 29359591

Bone marrow mesenchymal stem cells suppress IL-9 in adjuvant-induced arthritis.

Sahar Sobhy Abd-Elhalem1, Nawal Zakaria Haggag1, Nashwa Ahmed El-Shinnawy1.   

Abstract

Interleukin-9 (IL-9) has been shown to be upregulated in rheumatoid arthritis (RA). The exact role of IL-9 has not yet been effectively studied. Mesenchymal stem cells (MSCs) have shown a promising immunomodulatory role towards repairing cartilage and restoring joint function. One of the key problems influencing the therapeutic efficacy of stem cell therapy is the poor cell survival following transplantation. This is attributed to oxidative and inflammatory stresses at the injured sites. Hesperidin (Hsd), a flavanone present in citrus fruits, has been studied as potential therapeutic agents that have anti-oxidant and anti-inflammatory activities. The objective of this study is to evaluate the therapeutic paracrine action of bone marrow MSCs on the IL-9 level in adjuvant-induced arthritis (AIA) and the enhancement effect of Hsd on transplanted MSCs. Articular tissue inflammation and cartilage damage were assessed by histological scoring. Antinuclear autoantibodies, tumour necrosis factor-alpha (TNF-α), IL-9, IL-4, interferon gamma (IFN-δ), and transforming growth factor-beta1 (TGF-β1), as well as malondialdehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD) levels, were assessed in spleen tissue homogenates after treatment with MSCs either alone or combined with Hsd for 4 weeks in an AIA rat model. Results of this study confirmed that MSCs decreased IL-9 levels in AIA and provide novel insights into the application of Hsd on MSC-based treatments. Highlights Adjuvant-induced arthritis (AIA) is one of the most widely used models that has a great similarity to rheumatoid arthritis (RA). Few studies in recent years have estimated IL-9 in rheumatic diseases and it remains an understudied cytokine. For the first time, bone marrow mesenchymal stem cells (MSCs) therapy has a vital role in splenocytes IL-9 level and further studies are required. Combined therapy of MSCs with antioxidants as hesperidin (Hsd) can alleviate oxidative stress and enhance stem cells immunomodulatory action.

Entities:  

Keywords:  Interleukin-9; adjuvant-induced arthritis; bone marrow mesenchymal stem cells; hesperidin; spleen

Mesh:

Substances:

Year:  2018        PMID: 29359591     DOI: 10.1080/08916934.2018.1428956

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  4 in total

Review 1.  Mechanical regulation of nucleocytoplasmic translocation in mesenchymal stem cells: characterization and methods for investigation.

Authors:  Lucia Boeri; Diego Albani; Manuela Teresa Raimondi; Emanuela Jacchetti
Journal:  Biophys Rev       Date:  2019-10-18

Review 2.  The emerging antioxidant paradigm of mesenchymal stem cell therapy.

Authors:  Rhian Stavely; Kulmira Nurgali
Journal:  Stem Cells Transl Med       Date:  2020-06-04       Impact factor: 6.940

Review 3.  Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.

Authors:  Alexander Markov; Lakshmi Thangavelu; Surendar Aravindhan; Angelina Olegovna Zekiy; Mostafa Jarahian; Max Stanley Chartrand; Yashwant Pathak; Faroogh Marofi; Somayeh Shamlou; Ali Hassanzadeh
Journal:  Stem Cell Res Ther       Date:  2021-03-18       Impact factor: 6.832

4.  Intravenous injection of autologous bone marrow-derived mesenchymal stem cells on the gene expression and plasma level of CCL5 in refractory rheumatoid arthritis.

Authors:  Mina Alavi; Jalil Tavakkol-Afshari; Zhaleh Shariati-Sarabi; Arezoo Gowhari Shabgah; Mohsen Ghoryani; Ali Ghasemi; Mojgan Mohammadi
Journal:  J Res Med Sci       Date:  2020-12-30       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.